A pilot study showing differences in glycosylation patterns of IgG subclasses induced by pneumococcal, meningococcal, and two types of influenza vaccines
Version of Record online: 22 MAY 2014
© 2014 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Immunity, Inflammation and Disease
Volume 2, Issue 2, pages 76–91, August 2014
How to Cite
Vestrheim, A. C., Moen, A., Egge-Jacobsen, W., Reubsaet, L., Halvorsen, T. G., Bratlie, D. B., Paulsen, B. S. and Michaelsen, T. E. (2014), A pilot study showing differences in glycosylation patterns of IgG subclasses induced by pneumococcal, meningococcal, and two types of influenza vaccines. Immunity, Inflammation and Dis, 2: 76–91. doi: 10.1002/iid3.22
This work was supported by a FUGE grant from The Research Council of Norway to Glyconor, grant number 183613 and funds from the Norwegian Institute of Public Health and School of Pharmacy, University of Oslo.
- Issue online: 26 JUL 2014
- Version of Record online: 22 MAY 2014
- Manuscript Accepted: 8 APR 2014
- Manuscript Revised: 2 MAR 2014
- Manuscript Received: 18 NOV 2013
- The Research Council of Norway. Grant Number: 183613
- Norwegian Institute of Public Health
- School of Pharmacy, University of Oslo
Additional supporting information may be found in the online version of this article at the publisher's web-site.
Table S1. Specific IgG1 and IgG3 antibodies from meningococcal vaccinees, portrayed as µg/mL.
Table S2. Displaying mass to charge (m/z) of 20 IgG3 glycoforms with a different amino acid sequence.
Table S3. The minor responding subclass from the different vaccines, displayed as increase (), decrease (), or no change () in sugar composition observed at day 30 and day 90 after immunization, compared to the sample taken before immunization. Two of the vaccinees that received the pneumococcal vaccine had their second and third sample collected at day 14 and day 26, not day 30 and day 90 as the others. The results were however similar, so to ease presentation their time points were presented as day 30 and 90.
Table S4. The seven meningococcal vaccinees were previously tested for serum bactericidal activity and opsonaphagocytic activity. Results are shown as reciprocal titers, published previously .
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.